Schistosomiasis vaccines

Reference

• Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet 2006; 368:1106 - 18; http://dx.doi.org/10.1016/S0140-6736(06)69440-3; PMID: 16997665
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, Sachs JD, et al. Control of neglected tropical diseases. N Engl J Med 2007; 357:1018 - 27; http://dx.doi.org/10.1056/NEJMra064142; PMID: 17804846
   PubMed Web of Science ®Google Scholar
• Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 2006; 6:411 - 25; http://dx.doi.org/10.1016/S1473-3099(06)70521-7; PMID: 16790382
   PubMed Web of Science ®Google Scholar
• Gray DJ, McManus DP, Li Y, Williams GM, Bergquist R, Ross AG. Schistosomiasis elimination: lessons from the past guide the future. Lancet Infect Dis 2010; 10:733 - 6; http://dx.doi.org/10.1016/S1473-3099(10)70099-2; PMID: 20705513
   PubMed Web of Science ®Google Scholar
• Karanja DM, Hightower AW, Colley DG, Mwinzi PN, Galil K, Andove J, et al. Resistance to reinfection with Schistosoma mansoni in occupationally exposed adults and effect of HIV-1 co-infection on susceptibility to schistosomiasis: a longitudinal study. Lancet 2002; 360:592 - 6; http://dx.doi.org/10.1016/S0140-6736(02)09781-7; PMID: 12241930
   PubMed Web of Science ®Google Scholar
• King CH. Parasites and poverty: the case of schistosomiasis. Acta Trop 2010; 113:95 - 104; http://dx.doi.org/10.1016/j.actatropica.2009.11.012; PMID: 19962954
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Bundy DAP, Beegle K, Brooker S, Drake L, de SN et al. Helminth Infections: Soil-transmitted Helminth Infections and Schistosomiasis. 2006.
   Google Scholar
• Hotez PJ, Engels D, Fenwick A, Savioli L. Africa is desperate for praziquantel. Lancet 2010; 376:496 - 8; http://dx.doi.org/10.1016/S0140-6736(10)60879-3; PMID: 20709217
   PubMed Web of Science ®Google Scholar
• Black CL, Muok EM, Mwinzi PN, Carter JM, Karanja DM, Secor WE, et al. Increases in levels of schistosome-specific immunoglobulin E and CD23(+) B cells in a cohort of Kenyan children undergoing repeated treatment and reinfection with Schistosoma mansoni. J Infect Dis 2010; 202:399 - 405; http://dx.doi.org/10.1086/653828; PMID: 20560767
   PubMed Web of Science ®Google Scholar
• Bergquist R, Utzinger J, McManus DP. Trick or treat: the role of vaccines in integrated schistosomiasis control. PLoS Negl Trop Dis 2008; 2:e244; http://dx.doi.org/10.1371/journal.pntd.0000244; PMID: 18575619
   PubMed Web of Science ®Google Scholar
• Doenhoff MJ, Hagan P, Cioli D, Southgate V, Pica-Mattoccia L, Botros S, et al. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology 2009; 136:1825 - 35; http://dx.doi.org/10.1017/S0031182009000493; PMID: 19281637
   PubMed Web of Science ®Google Scholar
• McManus DP, Loukas A. Current status of vaccines for schistosomiasis. Clin Microbiol Rev 2008; 21:225 - 42; http://dx.doi.org/10.1128/CMR.00046-07; PMID: 18202444
   PubMed Web of Science ®Google Scholar
• Berriman M, Haas BJ, LoVerde PT, Wilson RA, Dillon GP, Cerqueira GC, et al. The genome of the blood fluke Schistosoma mansoni. Nature 2009; 460:352 - 8; http://dx.doi.org/10.1038/nature08160; PMID: 19606141
   PubMed Web of Science ®Google Scholar
• James CE, Hudson AL, Davey MW. An update on P-glycoprotein and drug resistance in Schistosoma mansoni. Trends Parasitol 2009; 25:538 - 9; http://dx.doi.org/10.1016/j.pt.2009.09.007; PMID: 19850522
   PubMed Web of Science ®Google Scholar
• Bergquist NR, Leonardo LR, Mitchell GF. Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach?. Trends Parasitol 2005; 21:112 - 7; http://dx.doi.org/10.1016/j.pt.2005.01.001; PMID: 15734657
   PubMed Web of Science ®Google Scholar
• Siddiqui AA, Ahmad G, Damian RT, Kennedy RC. Experimental vaccines in animal models for schistosomiasis. Parasitol Res 2008; 102:825 - 33; http://dx.doi.org/10.1007/s00436-008-0887-6; PMID: 18259777
   PubMed Web of Science ®Google Scholar
• Hagan P, Sharaf O. Schistosomiasis vaccines. Expert Opin Biol Ther 2003; 3:1271 - 8; http://dx.doi.org/10.1517/14712598.3.8.1271; PMID: 14640953
   PubMed Web of Science ®Google Scholar
• Lebens M, Sun JB, Czerkinsky C, Holmgren J. Current status and future prospects for a vaccine against schistosomiasis. Expert Rev Vaccines 2004; 3:315 - 28; http://dx.doi.org/10.1586/14760584.3.3.315; PMID: 15176948
   PubMedGoogle Scholar
• Rappuoli R, Aderem A. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 2011; 473:463 - 9; http://dx.doi.org/10.1038/nature10124; PMID: 21614073
   PubMed Web of Science ®Google Scholar
• Smythies LE, Betts C, Coulson PS, Dowling MA, Wilson RA. Kinetics and mechanism of effector focus formation in the lungs of mice vaccinated with irradiated cercariae of Schistosoma mansoni. Parasite Immunol 1996; 18:359 - 69; http://dx.doi.org/10.1046/j.1365-3024.1996.d01-115.x; PMID: 9229389
   PubMed Web of Science ®Google Scholar
• Cutts L, Wilson RA. Elimination of a primary schistosome infection from rats coincides with elevated IgE titres and mast cell degranulation. Parasite Immunol 1997; 19:91 - 102; http://dx.doi.org/10.1046/j.1365-3024.1997.d01-184.x; PMID: 9076811
   PubMed Web of Science ®Google Scholar
• Wilson RA, Langermans JA, Van Dam GJ, Vervenne RA, Hall SL, Borges WC, et al. Elimination of Schistosoma mansoni Adult Worms by Rhesus Macaques: Basis for a Therapeutic Vaccine?. PLoS Negl Trop Dis 2008; 2:e290; http://dx.doi.org/10.1371/journal.pntd.0000290; PMID: 18820739
   PubMed Web of Science ®Google Scholar
• Hagan P, Blumenthal UJ, Dunn D, Simpson AJ, Wilkins HA. Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium. Nature 1991; 349:243 - 5; http://dx.doi.org/10.1038/349243a0; PMID: 1898985
   PubMed Web of Science ®Google Scholar
• Hagan P. Reinfection, exposure and immunity in human schistosomiasis. Parasitol Today 1992; 8:12 - 6; http://dx.doi.org/10.1016/0169-4758(92)90303-J; PMID: 15463518
   PubMedGoogle Scholar
• Meeusen EN, Walker J, Peters A, Pastoret PP, Jungersen G. Current status of veterinary vaccines. [table.] Clin Microbiol Rev 2007; 20:489 - 510; http://dx.doi.org/10.1128/CMR.00005-07; PMID: 17630337
   PubMed Web of Science ®Google Scholar
• Olson CL, Acosta LP, Hochberg NS, Olveda RM, Jiz M, McGarvey ST, et al. Anemia of inflammation is related to cognitive impairment among children in Leyte, the Philippines. PLoS Negl Trop Dis 2009; 3:e533; http://dx.doi.org/10.1371/journal.pntd.0000533; PMID: 19847303
   PubMed Web of Science ®Google Scholar
• Bergquist R. Prospects of vaccination against schistosomiasis. Scand J Infect Dis Suppl 1990; 76:60 - 71; PMID: 2102021
   PubMedGoogle Scholar
• Todd CW, Colley DG. Practical and ethical issues in the development of a vaccine against schistosomiasis mansoni. Am J Trop Med Hyg 2002; 66:348 - 58; PMID: 12164288
   PubMed Web of Science ®Google Scholar
• Bickle QD. Radiation-attenuated schistosome vaccination–a brief historical perspective. Parasitology 2009; 136:1621 - 32; http://dx.doi.org/10.1017/S0031182009005848; PMID: 19327194
   PubMed Web of Science ®Google Scholar
• Hewitson JP, Hamblin PA, Mountford AP. Immunity induced by the radiation-attenuated schistosome vaccine. Parasite Immunol 2005; 27:271 - 80; http://dx.doi.org/10.1111/j.1365-3024.2005.00764.x; PMID: 16138848
   PubMed Web of Science ®Google Scholar
• Kumar P, Ramaswamy K. Vaccination with irradiated cercariae of Schistosoma mansoni preferentially induced the accumulation of interferon-gamma producing T cells in the skin and skin draining lymph nodes of mice. . Parasitol Int. 1999; 48:109 - 19; http://dx.doi.org/10.1016/S1383-5769(99)00008-2; PMID: 11269272
   PubMedGoogle Scholar
• Jankovic D, Wynn TA, Kullberg MC, Hieny S, Caspar P, James S, et al. Optimal vaccination against Schistosoma mansoni requires the induction of both B cell- and IFN-gamma-dependent effector mechanisms. J Immunol 1999; 162:345 - 51; PMID: 9886405
   PubMed Web of Science ®Google Scholar
• Dunne DW, Butterworth AE, Fulford AJ, Kariuki HC, Langley JG, Ouma JH, et al. Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to reinfection. Eur J Immunol 1992; 22:1483 - 94; http://dx.doi.org/10.1002/eji.1830220622; PMID: 1601036
   PubMed Web of Science ®Google Scholar
• Dunne DW, Butterworth AE, Fulford AJ, Ouma JH, Sturrock RF. Human IgE responses to Schistosoma mansoni and resistance to reinfection. Mem Inst Oswaldo Cruz 1992; 87:Suppl 4 99 - 103; http://dx.doi.org/10.1590/S0074-02761992000800014; PMID: 1343933
   PubMedGoogle Scholar
• Pinot de Moria A, Fulford AJ, Kabatereine NB, Ouma JH, Booth M, Dunne DW. Analysis of complex patterns of human exposure and immunity to Schistosomiasis mansoni: the influence of age, sex, ethnicity and IgE. PLoS Negl Trop Dis 2010; 4:e820; http://dx.doi.org/10.1371/journal.pntd.0000820; PMID: 20856909
   PubMedGoogle Scholar
• Kurtis JD, Friedman JF, Leenstra T, Langdon GC, Wu HW, Manalo DL, et al. Pubertal development predicts resistance to infection and reinfection with Schistosoma japonicum. Clin Infect Dis 2006; 42:1692 - 8; http://dx.doi.org/10.1086/504326; PMID: 16705573
   PubMed Web of Science ®Google Scholar
• Olds GR. New insights into the observed age-specific resistance to reinfection with Schistosoma japonicum. Clin Infect Dis 2006; 42:1699 - 701; http://dx.doi.org/10.1086/504331; PMID: 16705574
   PubMed Web of Science ®Google Scholar
• Butterworth AE, Dunne DW, Fulford AJ, Thorne KJ, Gachuhi K, Ouma JH, et al. Human immunity to Schistosoma mansoni: observations on mechanisms, and implications for control. Immunol Invest 1992; 21:391 - 407; http://dx.doi.org/10.3109/08820139209069381; PMID: 1428017
   PubMed Web of Science ®Google Scholar
• Ganley-Leal LM, Mwinzi PN, Cetre-Sossah CB, Andove J, Hightower AW, Karanja DM, et al. Correlation between eosinophils and protection against reinfection with Schistosoma mansoni and the effect of human immunodeficiency virus type 1 coinfection in humans. Infect Immun 2006; 74:2169 - 76; http://dx.doi.org/10.1128/IAI.74.4.2169-2176.2006; PMID: 16552047
   PubMed Web of Science ®Google Scholar
• Leenstra T, Acosta LP, Wu HW, Langdon GC, Solomon JS, Manalo DL, et al. T-helper-2 cytokine responses to Sj97 predict resistance to reinfection with Schistosoma japonicum. Infect Immun 2006; 74:370 - 81; http://dx.doi.org/10.1128/IAI.74.1.370-381.2006; PMID: 16368992
   PubMed Web of Science ®Google Scholar
• Mwinzi PN, Ganley-Leal L, Black CL, Secor WE, Karanja DM, Colley DG. Circulating CD23+ B cell subset correlates with the development of resistance to Schistosoma mansoni reinfection in occupationally exposed adults who have undergone multiple treatments. J Infect Dis 2009; 199:272 - 9; http://dx.doi.org/10.1086/595792; PMID: 19072134
   PubMed Web of Science ®Google Scholar
• Bergquist R, Utzinger J, Chollet J, Shu-Hua X, Weiss NA, Tanner M. Triggering of high-level resistance against Schistosoma mansoni reinfection by artemether in the mouse model. Am J Trop Med Hyg 2004; 71:774 - 7; PMID: 15642970
   PubMed Web of Science ®Google Scholar
• Bethony JM, Cole RN, Guo X, Kamhawi S, Lightowlers MW, Loukas A, et al. Vaccines to combat the neglected tropical diseases. Immunol Rev 2011; 239:237 - 70; http://dx.doi.org/10.1111/j.1600-065X.2010.00976.x; PMID: 21198676
   PubMed Web of Science ®Google Scholar
• Capron A, Dessaint JP, Capron M, Pierce RJ. Vaccine strategies against schistosomiasis. Mem Inst Oswaldo Cruz 1992; 87:Suppl 4 19 - 27; http://dx.doi.org/10.1590/S0074-02761992000800003; PMID: 1343894
   PubMedGoogle Scholar
• Hagan P. Schistosomiasis–a rich vein of research. Parasitology 2009; 136:1611 - 9; http://dx.doi.org/10.1017/S003118200999093X; PMID: 19691867
   PubMed Web of Science ®Google Scholar
• Capron A, Riveau G, Capron M, Trottein F. Schistosomes: the road from host-parasite interactions to vaccines in clinical trials. Trends Parasitol 2005; 21:143 - 9; http://dx.doi.org/10.1016/j.pt.2005.01.003; PMID: 15734662
   PubMed Web of Science ®Google Scholar
• Tendler M, Vilar MM, Brito CA, Freire NM, Katz N, Simpson A. Vaccination against schistosomiasis and fascioliasis with the new recombinant antigen Sm14: potential basis of a multi-valent anti-helminth vaccine?. Mem Inst Oswaldo Cruz 1995; 90:255 - 6; http://dx.doi.org/10.1590/S0074-02761995000200022; PMID: 8531667
   PubMed Web of Science ®Google Scholar
• Tendler M, Simpson AJ. The biotechnology-value chain: development of Sm14 as a schistosomiasis vaccine. Acta Trop 2008; 108:263 - 6; http://dx.doi.org/10.1016/j.actatropica.2008.09.002; PMID: 18834847
   PubMed Web of Science ®Google Scholar
• Siddiqui AA, Zhou Y, Podesta RB, Karcz SR, Tognon CE, Strejan GH, et al. Characterization of Ca(2+)-dependent neutral protease (calpain) from human blood flukes, Schistosoma mansoni. Biochim Biophys Acta 1993; 1181:37 - 44; PMID: 8457603
   PubMed Web of Science ®Google Scholar
• Ahmad G, Zhang W, Torben W, Haskins C, Diggs S, Noor Z, et al. Prime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine. Parasitol Res 2009; 105:1767 - 77; http://dx.doi.org/10.1007/s00436-009-1646-z; PMID: 19809833
   PubMed Web of Science ®Google Scholar
• Ahmad G, Torben W, Zhang W, Wyatt M, Siddiqui AA. Sm-p80-based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni. Parasite Immunol 2009; 31:156 - 61; http://dx.doi.org/10.1111/j.1365-3024.2008.01091.x; PMID: 19222788
   PubMed Web of Science ®Google Scholar
• Ahmad G, Zhang W, Torben W, Damian RT, Wolf RF, White GL, et al. Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model. Vaccine 2009; 27:2830 - 7; http://dx.doi.org/10.1016/j.vaccine.2009.02.096; PMID: 19366570
   PubMed Web of Science ®Google Scholar
• Ahmad G, Zhang W, Torben W, Noor Z, Siddiqui AA. Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice. Int J Infect Dis 2010; 14:e781 - 7; http://dx.doi.org/10.1016/j.ijid.2010.02.2266; PMID: 20630783
   PubMed Web of Science ®Google Scholar
• Ahmad G, Zhang W, Torben W, Ahrorov A, Damian RT, Wolf RF et al. Preclinical Prophylactic Efficacy Testing of Sm-p80-Based Vaccine in a Nonhuman Primate Model of Schistosoma mansoni Infection and Immunoglobulin G and E Responses to Sm-p80 in Human Serum Samples From an Area Where Schistosomiasis Is Endemic. J.Infect.Dis. 2011.
   Google Scholar
• Siddiqui AA, Phillips T, Charest H, Podesta RB, Quinlin ML, Pinkston JR, et al. Enhancement of Sm-p80 (large subunit of calpain) induced protective immunity against Schistosoma mansoni through co-delivery of interleukin-2 and interleukin-12 in a DNA vaccine formulation. Vaccine 2003; 21:2882 - 9; http://dx.doi.org/10.1016/S0264-410X(03)00159-2; PMID: 12798631
   PubMed Web of Science ®Google Scholar
• Siddiqui AA, Phillips T, Charest H, Podesta RB, Quinlin ML, Pinkston JR, et al. Induction of protective immunity against Schistosoma mansoni via DNA priming and boosting with the large subunit of calpain (Sm-p80): adjuvant effects of granulocyte-macrophage colony-stimulating factor and interleukin-4. Infect Immun 2003; 71:3844 - 51; http://dx.doi.org/10.1128/IAI.71.7.3844-3851.2003; PMID: 12819068
   PubMed Web of Science ®Google Scholar
• Siddiqui AA, Pinkston JR, Quinlin ML, Kavikondala V, Rewers-Felkins KA, Phillips T, et al. Characterization of protective immunity induced against Schistosoma mansoni via DNA priming with the large subunit of calpain (Sm-p80) in the presence of genetic adjuvants. Parasite 2005; 12:3 - 8; PMID: 15828575
   PubMed Web of Science ®Google Scholar
• Siddiqui AA, Pinkston JR, Quinlin ML, Saeed Q, White GL, Shearer MH, et al. Characterization of the immune response to DNA vaccination strategies for schistosomiasis candidate antigen, Sm-p80 in the baboon. Vaccine 2005; 23:1451 - 6; http://dx.doi.org/10.1016/j.vaccine.2004.09.018; PMID: 15670880
   PubMed Web of Science ®Google Scholar
• Torben W, Ahmad G, Zhang W, Siddiqui AA. Role of antibodies in Sm-p80-mediated protection against Schistosoma mansoni challenge infection in murine and nonhuman primate models. Vaccine 2011; 29:2262 - 71; http://dx.doi.org/10.1016/j.vaccine.2011.01.040; PMID: 21277404
   PubMed Web of Science ®Google Scholar
• Zhang W, Ahmad G, Torben W, Noor Z, Le L, Damian RT, et al. Sm-p80-based DNA vaccine provides baboons with levels of protection against Schistosoma mansoni infection comparable to those achieved by the irradiated cercarial vaccine. J Infect Dis 2010; 201:1105 - 12; http://dx.doi.org/10.1086/651147; PMID: 20187746
   PubMed Web of Science ®Google Scholar
• Zhang W, Ahmad G, Torben W, Siddiqui AA. Sm-p80-based DNA vaccine made in a human use approved vector VR1020 protects against challenge infection with Schistosoma mansoni in mouse. Parasite Immunol 2010; 32:252 - 8; http://dx.doi.org/10.1111/j.1365-3024.2009.01181.x; PMID: 20398225
   PubMed Web of Science ®Google Scholar
• Zhang W, Ahmad G, Torben W, Siddiqui AA. Schistosoma mansoni antigen Sm-p80: Prophylactic efficacy of a vaccine formulated in human approved plasmid vector and adjuvant (VR 1020 and alum). Acta Trop 2011; 118:142 - 51; http://dx.doi.org/10.1016/j.actatropica.2011.01.010; PMID: 21334302
   PubMed Web of Science ®Google Scholar
• Ohta N, Kumagai T, Maruyama H, Yoshida A, He Y, Zhang R. Research on calpain of Schistosoma japonicum as a vaccine candidate. Parasitol. Int. 2004; 53:175 - 81; http://dx.doi.org/10.1016/j.parint.2004.01.007; PMID: 15081949
   PubMed Web of Science ®Google Scholar
• Zhang R, Yoshida A, Kumagai T, Kawaguchi H, Maruyama H, Suzuki T, et al. Vaccination with calpain induces a Th1-biased protective immune response against Schistosoma japonicum. Infect Immun 2001; 69:386 - 91; http://dx.doi.org/10.1128/IAI.69.1.386-391.2001; PMID: 11119528
   PubMed Web of Science ®Google Scholar
• Hota-Mitchell S, Siddiqui AA, Dekaban GA, Smith J, Tognon C, Podesta RB. Protection against Schistosoma mansoni infection with a recombinant baculovirus-expressed subunit of calpain. Vaccine 1997; 15:1631 - 40; http://dx.doi.org/10.1016/S0264-410X(97)00081-9; PMID: 9364694
   PubMed Web of Science ®Google Scholar
• Hota-Mitchell S, Clarke MW, Podesta RB, Dekaban GA. Recombinant vaccinia viruses and gene gun vectors expressing the large subunit of Schistosoma mansoni calpain used in a murine immunization-challenge model. Vaccine 1999; 17:1338 - 54; http://dx.doi.org/10.1016/S0264-410X(98)00391-0; PMID: 10195769
   PubMed Web of Science ®Google Scholar
• Jankovic D, Aslund L, Oswald IP, Caspar P, Champion C, Pearce E, et al. Calpain is the target antigen of a Th1 clone that transfers protective immunity against Schistosoma mansoni. J Immunol 1996; 157:806 - 14; PMID: 8752932
   PubMed Web of Science ®Google Scholar
• El Ridi R, Tallima H. Schistosoma mansoni ex vivo lung-stage larvae excretory-secretory antigens as vaccine candidates against schistosomiasis. Vaccine 2009; 27:666 - 73; http://dx.doi.org/10.1016/j.vaccine.2008.11.039; PMID: 19056448
   PubMed Web of Science ®Google Scholar
• El Ridi R, Tallima H, Mahana N, Dalton JP. Innate immunogenicity and in vitro protective potential of Schistosoma mansoni lung schistosomula excretory-secretory candidate vaccine antigens. Microbes Infect 2010; 12:700 - 9; http://dx.doi.org/10.1016/j.micinf.2010.04.012; PMID: 20452455
   PubMed Web of Science ®Google Scholar
• Osada Y, Kumagai T, Hato M, Suzuki T, El-Malky M, Asahi H, et al. Establishment of Schistosoma japonicum calpain-specific mouse T cell hybridomas and identification of a T cell epitope that stimulates IFNgamma production. Vaccine 2005; 23:2813 - 9; http://dx.doi.org/10.1016/j.vaccine.2004.10.042; PMID: 15780729
   PubMed Web of Science ®Google Scholar
• Tran MH, Pearson MS, Bethony JM, Smyth DJ, Jones MK, Duke M, et al. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis. Nat Med 2006; 12:835 - 40; http://dx.doi.org/10.1038/nm1430; PMID: 16783371
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Bethony JM, Diemert DJ, Pearson M, Loukas A. Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat Rev Microbiol 2010; 8:814 - 26; http://dx.doi.org/10.1038/nrmicro2438; PMID: 20948553
   PubMed Web of Science ®Google Scholar
• Zhang W, Li J, Duke M, Jones MK, Kuang L, Zhang J, et al. Inconsistent Protective Efficacy and Marked Polymorphism Limits the Value of Schistosoma japonicum Tetraspanin-2 as a Vaccine Target. PLoS Negl Trop Dis 2011; 5:e1166; http://dx.doi.org/10.1371/journal.pntd.0001166; PMID: 21655308
   PubMedGoogle Scholar